Loading...
11 Middle East and Africa Hyperglycemics Reports
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Merck, Novartis, Boehringer Ingelheim, AstraZeneca, Eli Lilly and Company
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Novo Nordisk, Glenmark Pharmaceuticals, KISSEI PHARMACEUTICAL, Novartis, Biocon
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Novo Nordisk, Sanofi, Eli Lilly and Company, Wockhardt, Pfizer
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Glenmark Pharmaceuticals, Novartis, KISSEI PHARMACEUTICAL, Biocon, Novo Nordisk
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Abbott Laboratories, Sanofi, Mylan, Lupin, Aurobindo Pharma
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi, Novo Nordisk, Biocon, Eli Lilly and Company, Julphar
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Wockhardt
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Novo Nordisk, Eli Lilly and Company, Pfizer, Sanofi, Biocon
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi, Pfizer, Merck, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories
Region Covered: Middle East and Africa
Study Period: 2019 - 2030
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Bristol-Myers Squibb, Glenmark Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Merck
Filter Reports
By Countries
